FDA Approves Tudriqev for Advanced Melanoma After Two Prior Rejections

The U.S. Food and Drug Administration granted accelerated approval on August 6 to Tudriqev, a genetically modified oncolytic viral therapy, in combination with nivolumab for adults with unresectable advanced cutaneous me...

2 hours agohealthUS